Evidence map›Paper›PMID 36844691›Full record

ArticleClinical and experimental vaccine research2023

Individual expression and processing of hepatitis C virus E1/E2 epitopes-based DNA vaccine candidate in healthy humans' peripheral blood mononuclear cells.

Rola Nadeem, Amany Sayed Maghraby, Dina Nadeem Abd-Elshafy, Ahmed Barakat Barakat, Mahmoud Mohamed Bahgat

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental vaccine research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rola NadeemDepartment of Therapeutic Chemistry, Pharmaceutical and Drug Industries Research Institute, National Research Center, Cairo, Egypt.ORCID https://orcid.org/0000-0002-4093-2270
Amany Sayed MaghrabyDepartment of Therapeutic Chemistry, Pharmaceutical and Drug Industries Research Institute, National Research Center, Cairo, Egypt.ORCID https://orcid.org/0000-0002-9723-5011
Dina Nadeem Abd-ElshafyImmune- and Bio-markers for Infection Research Group, Center of Excellence for Advanced Sciences, National Research Center, Cairo, Egypt.ORCID https://orcid.org/0000-0002-2777-2487
Ahmed Barakat BarakatMicrobiology department, Faculty of Science, Ain Shams University, Cairo, Egypt.ORCID https://orcid.org/0000-0002-0178-1174
Mahmoud Mohamed BahgatDepartment of Therapeutic Chemistry, Pharmaceutical and Drug Industries Research Institute, National Research Center, Cairo, Egypt.ORCID https://orcid.org/0000-0002-6485-8722

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The development and study of hepatitis C virus (HCV) vaccine candidates' individualized responses are of great importance. Here we report on an HCV DNA vaccine candidate based on selected envelope (E1/E2) epitopes. Besides, we assessed its expression and processing in human peripheral blood mononuclear cells (PBMCs) and Materials and Methods: HCV E1/E2 DNA construct (EC) was designed. The antigen expression of EC was assayed in PBMCs of five HCV-uninfected donors via a real-time quantitative polymerase chain reaction. Serum samples from 20 HCV antibody-positive patients were used to detect each individual PBMCs expressed antigens via enzyme-linked immunosorbent assay. Two groups, five Swiss albino mice each, were immunized with the EC or a control construct. The absolute count of lymph nodes' CD4 Results: Donors' PBMCs showed different levels of EC expression, ranging between 0.83-2.61-fold in four donors, while donor-3 showed 34.53-fold expression. The antigens expressed in PBMCs were significantly reactive to the 20 HCV antibody repertoire (all p=0.0001). All showed comparable reactivity except for donor-3 showing the lowest reactivity level. The absolute count % of the CD4 Conclusion: The inter-individual variation in antigen expression and processing dominance was evident, showing independence in individuals' antigen expression and reactivity levels to antibodies. The described vaccine candidate might result in a promising natural immune response with a possibility of CD4

Indexed as

DNA vaccinesEnvelope proteinHepatitis C virusHuman peripheral blood mononuclear cellsIndividuality

Identifiers

PMID36844691
PMCPMC9950224

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.